Maze Therapeutics MAZE
NASDAQ MAZE
$35.03 +0.12 (+0.34%)
As of: Nov 10, 2026 · 2:15 PM EST

Maze Therapeutics (MAZE) Receivables (2026)

Updated

Maze Therapeutics (MAZE) posted Receivables of $20 million for Q1 2026.

Analysis

Maze Therapeutics (MAZE) Receivables (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 18.99 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 13.51 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 14.33 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 5.01 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 14.19 Bn
10 Maze Therapeutics 2.05 Bn 561.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 20.00 Mn
API Access

Maze Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=MAZE&period=max&api_key=YOUR_API_KEY